biostudies-literatureUnknown23(8)Bittrich MBayerisch–Tschechische HochschulagenturWilhelm Sander-StiftungDeutsche KrebshilfeJulius-Maximilians-Universität WürzburgUniversitätsklinikum WürzburgElse Kröner-Fresenius-StiftungInterdisziplinäres Zentrum für Klinische Forschung, Universitätsklinikum WürzburgIn addition to randomized clinical trials, consideration of Real-World Evidence is necessary for mirroring clinical reality. However, processing such evidence for large numbers of patients often requires considerable time and effort. This is particularly true for rare tumor diseases such as multiple myeloma (MM) or for adverse effects that occur even more rarely. In such cases, artificial intelligence is able to efficiently detect patients with rare conditions. One of these rare adverse events, and the most discussed, following bone protective treatment in MM is medication-related osteonecrosis of the jaw (MRONJ). The association of bone protective treatment to MM outcome has been intensively studied. However, the impact of MRONJ resulting from such treatment on MM prognosis and outcome isClinical and experimental medicine5215-5226https://www.ebi.ac.uk/biostudies/studies/S-EPMC10725344biostudies-literatureDoes medication-related osteonecrosis of the jaw affect survival of patients with Multiple Myeloma?: Exploring a large single center database using artificial intelligence.PMC10725344Beilhack AKerscher AEinsele HKrebs MLoda SBittrich MKnop SZhou XKortum KMSolimando AGDanhof SRasche LAnton SHartmann SHetterich RfalseDoes medication-related osteonecrosis of the jaw affect survival of patients with Multiple Myeloma?: Exploring a large single center database using artificial intelligence.In addition to randomized clinical trials, consideration of Real-World Evidence is necessary for mirroring clinical reality. However, processing such evidence for large numbers of patients often requires considerable time and effort. This is particularly true for rare tumor diseases such as multiple myeloma (MM) or for adverse effects that occur even more rarely. In such cases, artificial intelligence is able to efficiently detect patients with rare conditions. One of these rare adverse events, and the most discussed, following bone protective treatment in MM is medication-related osteonecrosis of the jaw (MRONJ). The association of bone protective treatment to MM outcome has been intensively studied. However, the impact of MRONJ resulting from such treatment on MM prognosis and outcome is2023-01-01T00:00:00Z2023 Dec2026-06-03T12:00:10.118Z2025-04-04T12:52:07.333ZS-EPMC107253443780562010.1007/s10238-023-01100-6